Acarix

0.29 SEK

-1.19%

Less than 1K followers

ACARIX

First North Stockholm

Medical Equipment & Services

Health Care

-1.19 %
+2.48 %
+12.43 %
+8.02 %
+1.94 %
+30.11 %
-41.05 %
-72.65 %
-96.08 %

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Read more
Market cap
359.14M SEK
Turnover
88.19K SEK
Revenue
7.36M
EBIT %
-652.31 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.5
2026

Interim report Q1'26

17.6
2026

General meeting '26

13.8
2026

Interim report Q2'26

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Forum discussions
On my journey in search of a new Revenio, in a country where vague Finland-Swedish was spoken and which was ruled by Carl XVI Gustaf, I came across a company called Acarix. And I’m not comparing this to be a new Revenio. For the diagnosis of coronary artery disease, a common basic...
Expected SEK 79 million share issue now underway: https://acarix.com/wp-content/uploads/2021/11/acarixpralmeria-prospekteng.pdf
Tärkeimmät talousuutiset | Kauppalehti – 27 Jun 19 Acarix CADScor®System included in NICE guidelines (UK) Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä. Here’s a slightly older bulletin. An interesting product, which has...
Interesting that the analyst firm is also an advisor.. Are they also an investor?
Redeye’s website does have a Disclosures section for the company in question, which states whether Redeye owns the company. In this case, it does not. redeye.se Acarix Disclosures - Redeye Discover the latest equity research on Acarix.
PubMed Economic Analysis of the CADScor System for Ruling Out Coronary Artery... The CADScor System is a potentially cost-saving test for the diagnosis of CAD. When initiated before the use of non-invasive cardiac imaging tests such as computed tomography coronary angiography, the...
News from America has arrived; I don’t know how to post it here. Thanks in advance
Read more on our forum